Confirming a diagnosis of AD requires neuropathologic evidence of both amyloid plaques from Aβ peptides and NFTs composed of hyperphosphorylated and abnormally folded tau proteins [9]. The gene discussed is MAPT; the disease is Alzheimer disease.